Cerenome (CNSY) Earnings Date & Reports

Key Takeaways

• Cerenome is expected to report third-quarter 2026 results in late October or early November, with analyst consensus near a $0.92 per-share loss on roughly $750,000 in revenue.
• The quarter's headline is its CNSide diagnostics business, which disclosed 222 billed tests and $1.55 million in gross billings in a September 30 business update — though gross billings are not GAAP revenue.
• Second-quarter results set a cautious tone: a loss of $1.31 per share missed estimates, revenue of $411,000 fell short, and the stock dropped about 13% the following day.
• Investors are watching whether list-price billings convert into actual cash collections and how long the company's cash runway lasts.
• Beyond diagnostics, progress on the REYOBIQ radiotherapeutic pipeline and Medicare coverage remain key swing factors.
• For deeper context, explore Cerenome's Major News, Today's Price Move, Price Targets, and Forecast.
• Looking for fresh trade ideas? Browse Tickeron's Trending AI Robots.

Earnings Context and Why It Matters

Cerenome, formerly Plus Therapeutics, rebranded in August 2026 as a central nervous system (CNS) oncology company combining diagnostics, therapeutics, and data analytics. Its third-quarter report is a pivotal test of the commercial relaunch of CNSide, a cerebrospinal fluid (CSF) assay that detects tumor cells in patients whose cancer has spread to the fluid around the brain and spine. Because the company is clinical-stage and not yet profitable, investors focus less on headline revenue and more on operating momentum, cash collections, and whether the diagnostic strategy can fund its broader pipeline. A weak print could intensify concerns about cash runway, while a strong one could validate the rebranded business model.

Earnings Expectations

Wall Street consensus for Cerenome's third quarter of 2026 points to a loss of roughly $0.92 per share, with revenue near $750,000, according to analyst estimates. These figures carry significant uncertainty because CNSide's billed amounts are reported at list price, while revenue under generally accepted accounting principles (GAAP) is recognized after contractual allowances and price concessions — meaning recognized revenue is expected to be substantially lower than gross billings.

Management has already signaled preliminary Q3 operating metrics: 222 CNSide tests billed, representing $1.55 million in unaudited gross billings, with initial cash collections anticipated in the fourth quarter. The company also reported 158 million contracted covered lives for its lead Tumor Cell Enumeration (TCE) test and a favorable preliminary pricing decision from the Centers for Medicare & Medicaid Services (CMS) targeting a January 1, 2027 effective date. Investors will scrutinize how these billing figures translate into recognized revenue and whether the pace of test adoption meets the company's goal of a 1,250-test annualized run rate.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening — a useful complement when tracking an earnings event like Cerenome's. Explore the AI Screener to build your own watchlist around names poised for their next catalyst.

Market Reaction and Investor Sentiment

Sentiment heading into this report is cautious. CNSY shares have fallen sharply year-to-date, and the stock dropped about 13% the day after second-quarter results missed expectations, underscoring how sensitive the name is to earnings surprises. Analysts still maintain a broadly constructive stance, with price targets well above current levels, but the gap between list-price billings and actual cash collections has drawn skepticism from some observers. The key risk is that investors reprice the stock if recognized revenue and collection rates fail to match the optimism embedded in the company's gross-billing disclosures.

Forward Outlook and Key Factors to Monitor

The most important number to watch after this report is cash collected per test. Cerenome has shown it can generate orders and submit claims, but the economics of the CNSide business will only be proven when payers actually reimburse at meaningful rates. Management has pointed to initial cash collections beginning in the fourth quarter, so early collection data will be a critical signal.

Medicare is the next major catalyst. A published preliminary rate for the proprietary PLA code 0640U, targeted for January 1, 2027, could give private payers a benchmark to index against and accelerate reimbursement. Investors should also monitor coverage expansion toward the company's goal of roughly 200 million covered lives and beneficiaries by early 2027.

On the product side, Cerenome plans to launch its CSF Molecular Profile sequencing test and breast cancer protein expression assays in the fourth quarter, which could raise the value generated per specimen. Finally, cash runway and any additional financing remain central risks, given the company's ongoing operating losses and the substantial resources required to advance its REYOBIQ radiotherapeutic pipeline.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations